title: Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment.
abstract: Chronic granulomatous disease (CGD) is a rare immunodeficiency disorder in which phagocytic leukocytes fail to generate superoxide (O(2)(-)) and antimicrobial oxidants. The therapeutic validity of interferon-gamma (IFN-γ) has been well established in CGD patients but its underlying mechanisms remain poorly understood. One probable mechanism has been suggested to be modulation of nitric oxide (NO) release from phagocytic cells. Herein, we investigated NO production from neutrophil cells in CGD patients on treatment with IFN-γ in vivo and in vitro. We measured NO levels in sera from 19 CGD patients (group I: 7 patients treated with TMP-SMX, group II: 12 patients treated with TMP-SMX and IFN-γ simultaneously) and healthy control individuals (8 cases). We also measured NO production from neutrophils in both patients groups as well as in control group after adding 100 U IFN-γ in vitro. Our results showed that there was a significant difference between the groups in the NO levels of serum; patients who received IFN-γ had significantly higher amount of NO than the other groups. Besides, NO levels increased significantly after adding 100 U IFN-γ in vitro in three studied groups, considerably in the patients on treatment with IFN-γ. As a brief conclusion, the effect of IFN-γ in increasing NO production is obvious. This could be an explanation for the therapeutic effect of IFN-γ in patients with CGD as NO acts as a bactericidal agent and plays a role in host defense mechanism instead of O(2)(-).
authors.affiliation: Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Fariba
authors.initials: F
authors.lastname: Naderi beni
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Fattahi
authors.forename: Abbas
authors.initials: A
authors.lastname: Mirshafiey
authors.forename: Mohammad
authors.initials: M
authors.lastname: Ansari
authors.forename: Monireh
authors.initials: M
authors.lastname: Mohsenzadegan
authors.forename: Masoud
authors.initials: M
authors.lastname: Movahedi
authors.forename: Zahra
authors.initials: Z
authors.lastname: Pourpak
authors.forename: Mostafa
authors.initials: M
authors.lastname: Moin
mesh_terms: D000293:Adolescent; D000328:Adult; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D005260:Female; D006105:Granulomatous Disease, Chronic / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007223:Infant; D007371:Interferon-gamma / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D009566:Nitrates / Q000097:blood; D009569:Nitric Oxide / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D009573:Nitrites / Q000097:blood; D055815:Young Adult
chemical_list: D009566:Nitrates; D009573:Nitrites; D009569:Nitric Oxide; D007371:Interferon-gamma